← FDA DRUG APPROVALS

FDA ANDA · ANDA202252

FENOFIBRATE

Sponsor: APOTEX

APPLICATION
ANDA202252
TYPE
ANDA
ORIGINAL APPROVAL
2013-07-26
LATEST ACTION
2021-11-16
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

FENOFIBRATE (MICRONIZED)Prescription
FENOFIBRATE 130MG · CAPSULE · ORAL
FENOFIBRATE (MICRONIZED)Prescription
FENOFIBRATE 43MG · CAPSULE · ORAL

Approval history

2021-11-16Labeling · Supplement 9 · standardAP
2019-12-09Labeling · Supplement 6 · standardAP
2019-12-09Labeling · Supplement 4 · standardAP
2019-12-09Labeling · Supplement 7 · standardAP
2019-12-09Labeling · Supplement 5 · standardAP
2013-07-26OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →